CureVac NV (NAS:CVAC)
$ 4.34 0.45 (11.57%) Market Cap: 973.49 Mil Enterprise Value: 587.35 Mil PE Ratio: 0 PB Ratio: 2.00 GF Score: 69/100

CureVac NV at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 10:40PM GMT
Release Date Price: $9.1 (+7.69%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Perfect. Welcome to the afternoon sessions of the BofA Healthcare Conference. So I'm Geoff Meacham, and my colleague, Charlie Yang, is on the stage with me. We're thrilled today to have CureVac and CFO, Pierre Kemula. Welcome. Thank you very much.

Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board

Yes.

Questions & Answers

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Yes. So Pierre, maybe just give us a bit of a status update about how mRNA technology, obviously, brand new to the world, come COVID, but now we've seen an evolution of the technology. Give us kind of where you are relative to, say, Moderna or BioNTech and your biggest points of, I would say, differentiation in the technology as a starter?

Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board

Sure. So -- and thanks for the question. So we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot